ClinicalTrials.gg
RecruitingNCT07491445RASolute 303Updated Nov 16, 2026

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

A Phase 3 interventional study of daraxonrasib and gemcitabine in Pancreatic Cancer, Pancreatic Cancer Metastatic and PDAC, sponsored by Revolution Medicines, Inc.. Recruiting at 106 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Revolution Medicines, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 16, 2026First sites in 11 new countriesPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Planned enrollment
4th of 352
900 · median 37
Started
2026
with 5 others
Phase 3
31 of 369
5 open now
Primary completion
2028-04
later than 38 of 43 live
Registered
366th of 369
by date

Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 4th largest by planned enrollment of the 352 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 in phase 3, reaches primary completion later than 38 of the 43 other live ones, and was the 366th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Read the detailed description

This is a global, randomized, open-label, Phase 3 study designed to evaluate the efficacy and safety of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel compared with standard gemcitabine and nab-paclitaxel when given as first-line treatment in patients with metastatic pancreatic adenocarcinoma.

Patients will be randomized to one of three arms: daraxonrasib (Arm A), daraxonrasib + gemcitabine and nab-paclitaxel (Arm B), or gemcitabine and nab-paclitaxel (Arm C).

03

Conditions studied

  • Pancreatic Cancer
  • Pancreatic Cancer Metastatic
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma
  • Pancreatic Adenosquamous Carcinoma

Keywords

  • Pancreatic Cancer
  • PDAC
  • Pancreatic Ductal Adenocarcinoma
  • RAS
  • KRAS
  • NRAS
  • HRAS
  • RAS Wild-Type
  • RAS Mutation
  • Pancreatic Cancer Metastatic
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenosquamous Carcinoma
  • Pancreatic Adenocarcinoma
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old and has provided .
  • (ECOG) performance status of 0 or 1.
  • or cytologically confirmed pancreatic adenocarcinoma.
  • Diagnosis of disease ≤ 6 weeks prior to informed consent.
  • Documented RAS mutation status, either mutant or wild-type.
  • per v1.1.
  • Adequate organ function (bone marrow, liver, kidney, coagulation).
  • Able to take oral medications.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with systemic anticancer therapy in or locally advanced setting or prior RAS-targeted therapy in any treatment setting.
  • Active or known history of untreated central nervous system metastatic disease.
  • Any conditions that may affect the ability to take or absorb study drug.
  • Major surgery within 28 days prior to randomization.
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Arm A: daraxonrasib

    study drug

    Drug: daraxonrasib

  • Experimental
    Arm B: daraxonrasib + gemcitabine and nab-paclitaxel

    study drug in combination with chemotherapy

    Drug: daraxonrasib · Drug: gemcitabine · Drug: nab-paclitaxel

  • Active comparator
    Arm C: gemcitabine and nab-paclitaxel

    SOC chemotherapy

    Drug: gemcitabine · Drug: nab-paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) as assessed by blinded independent central review (BICR)

    Comparison of PFS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR.

    Time frame: Up to approximately 2 years

  2. Overall survival (OS)

    Comparison of OS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). OS is defined as the time from randomization until death from any cause.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. PFS as assessed by BICR

    Comparison of PFS of daraxonrasib (Arm A) versus gemcitabine and nab-paclitaxel (Arm C). PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per RECIST v1.1 and as assessed by BICR.

    Time frame: Up to approximately 2 years

  2. Overall survival (OS)

    Comparison of OS of daraxonrasib (Arm A) versus gemcitabine and nab-paclitaxel (Arm C). OS is defined as the time from randomization until death from any cause.

    Time frame: Up to approximately 2 years

  3. PFS as assessed by the Investigator

    Comparison of PFS of daraxonrasib (Arm A) versus gemcitabine and nab-paclitaxel (Arm C) and daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per RECIST v1.1 and as assessed by the investigator.

    Time frame: Up to approximately 2 years

  4. Objective response rate (ORR)

    Objective response is defined as partial response (PR) or complete response (CR) per RECIST v1.1, as assessed by BICR and the investigator.

    Time frame: Up to approximately 2 years

  5. Duration of response (DOR)

    DOR is defined as time from first evidence of objective response (PR or CR) to disease progression or death due to any cause, whichever occurs first, as assessed by BICR and the investigator.

    Time frame: Up to approximately 2 years

  6. Concentration of daraxonrasib in Arm A and B

    Pre-dose trough and post-dose blood concentrations of daraxonrasib at selected visits.

    Time frame: Up to Cycle 5 Day 1 (each cycle is 28 days)

  7. Health-related outcome assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26)

    EORTC QLQ-PAN26 consists of 26 items assessing patient-reported health-related quality of life, including symptoms and impacts. Change from baseline in the pain subscale scores will be evaluated, with higher scores indicating greater symptom burden.

    Time frame: Up to approximately 2 years

  8. Quality of life as assessed with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties), and an overall scale for global health status. Change from baseline in EORTC QLQ-C30 global health status will be assessed, with higher scores reflecting better functioning.

    Time frame: Up to approximately 2 years

  9. Incidence of adverse events (AEs)

    Percentage of patients with AEs as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5

    Time frame: Up to approximately 2 years

  10. Changes in vital signs

    Number of patients with clinically significant changes in vital signs

    Time frame: Up to approximately 2 years

  11. Changes in clinical laboratory test values

    Number of patients with changes from baseline in clinical laboratory test values

    Time frame: Up to approximately 2 years

07

Study locations

85 of 106 sites recruiting

Showing the first 100 of 106 sites across 21 countries. Choose a country and city above to see the rest.

08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's planned 25 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2028 → Apr 2028, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 24, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Apr 2028was Jun 2028
CompletionEst.
Mar 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
57 sites added — first sites in Netherlands, Spain, Belgium, Germany, Hong Kong and 6 more
All 11 countries

Netherlands, Spain, Belgium, Germany, Hong Kong, Italy, Denmark, Norway, Poland, Sweden, Switzerland

. 18 sites changed recruiting status (18 now active, not recruiting)
Show 18 sites
  • Mayo Clinic - Scottsdale · Phoenix, United StatesRecruiting→Active, not recruiting
  • Honor Health Research Institute · Scottsdale, United StatesRecruiting→Active, not recruiting
  • University of California Los Angeles Health - Hematology/Oncology · Los Angeles, United StatesRecruiting→Active, not recruiting
  • University of California San Francisco · San Francisco, United StatesRecruiting→Active, not recruiting
  • Mayo Clinic Cancer Center- Florida · Jacksonville, United StatesRecruiting→Active, not recruiting
  • H Lee Moffitt Cancer Center and Research Institute · Tampa, United StatesRecruiting→Active, not recruiting
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, United StatesRecruiting→Active, not recruiting
  • Dana-Farber Cancer Institute · Boston, United StatesRecruiting→Active, not recruiting
  • Mayo Clinic Cancer Center- Rochester · Rochester, United StatesRecruiting→Active, not recruiting
  • Memorial Sloan Kettering Cancer Center · New York, United StatesRecruiting→Active, not recruiting
  • Duke University Medical Center · Durham, United StatesRecruiting→Active, not recruiting
  • University of Cincinnati Cancer Center · Cincinnati, United StatesRecruiting→Active, not recruiting
  • SCRI Oncology Partners · Nashville, United StatesRecruiting→Active, not recruiting
  • SCRI - Texas Oncology Dallas · Dallas, United StatesRecruiting→Active, not recruiting
  • MD Anderson Cancer Center · Houston, United StatesRecruiting→Active, not recruiting
  • Huntsman Cancer Institute · Salt Lake City, United StatesRecruiting→Active, not recruiting
  • Virginia Cancer Specialists · Fairfax, United StatesRecruiting→Active, not recruiting
  • Virginia Mason Medical Center · Seattle, United StatesRecruiting→Active, not recruiting
Show 57 added (7 Spain, 6 Italy, 5 South Korea, 5 United Kingdom, 5 Belgium, 4 Australia, 4 Germany, 3 Netherlands, 3 Poland, 2 Taiwan, 2 Canada, 2 Hong Kong, 2 Norway, 2 Switzerland, 1 United States, 1 Singapore, 1 Austria, 1 Denmark, 1 Sweden)
  • Henry Ford Health System · Detroit, United States
  • Royal Brisbane and Women's Hospital · Herston, Australia
  • Austin Health, Olivia Newton-John Cancer Research & Wellness Centre · Heidelberg, Australia
  • Erasmus Medisch Centrum · Rotterdam, Netherlands
  • Dong-A University Hospital · Busan, South Korea
  • Severance Hospital, Yonsei University Health System · Seoul, South Korea
  • Asan Medical Center - PPDS · Seoul, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Universitario La Paz - PPDS · Madrid, Spain
  • Taipei Veterans General Hospital · Taipei, Taiwan
  • Sarah Cannon Research Institute UK · London, United Kingdom
  • St. George Hospital · Kogarah, Australia
  • Institut Jules Bordet · Anderlecht, Belgium
  • UZ Leuven (Univ Ziekenhuis Leuven) · Leuven, Belgium
  • Sunnybrook Research Institute · Toronto, Canada
  • Klinikum der Universitaet Muenchen Campus Grosshadern · München, Germany
  • The Chinese University of Hong Kong · Hong Kong, Hong Kong
  • Fondazione IRCCS Istituto Nazionale dei Tumori · Milan, Italy
  • Istituto Oncologico Veneto IRCCS · Padova, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
  • Azienda Ospedaliera Card. G. Panico · Tricase, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) · Verona, Italy
  • St. Antonius Ziekenhuis · Utrecht, Netherlands
  • National Cancer Centre Singapore · Singapore, Singapore
  • Kyungpook National University Chilgok Hospital · Daegu, South Korea
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Clínico Universitario de Valencia · Valencia, Spain
  • National Cheng Kung University Hospital · Tainan, Taiwan
  • The Clatterbridge Cancer Centre · Liverpool, United Kingdom
  • …and 27 more on the registry record
across 3 updates, Sep 30, 2026 – Nov 16, 2026
Primary completion
Jun 2028→Apr 2028
Nov 16, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedPrior treatment with systemic anticancer therapy in metastatic or locally advanced setting or prior RAS-targeted therapy in any treatment setting.
Nov 16, 2026
Primary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedProgression free survival (PFS) as assessed by blinded independent central review (BICR)Time frame: Up to approximately 2 years
  • DescriptionOverall survival (OS): how it is measured was reworded
Nov 16, 2026
Secondary outcomes
3 added, 2 description edited
What changed in the outcomes
  • AddedPFS as assessed by BICRTime frame: Up to approximately 2 years
  • AddedOverall survival (OS)Time frame: Up to approximately 2 years
  • AddedPFS as assessed by the InvestigatorTime frame: Up to approximately 2 years
  • DescriptionDuration of response (DOR): how it is measured was reworded
  • DescriptionObjective response rate (ORR): how it is measured was reworded
Nov 16, 2026
Site contacts
Changed at 14 sites. See the sites
Show 14 sites
  • Honor Health Research Institute · Scottsdale, United StatesContact removed c•••@honorhealth.com
  • University of California Los Angeles Health - Hematology/Oncology · Los Angeles, United StatesContact removed b•••@mednet.ucla.edu · •••0771
  • University of California San Francisco · San Francisco, United StatesContact removed •••7070
  • H Lee Moffitt Cancer Center and Research Institute · Tampa, United StatesContact removed c•••@moffitt.org · •••3691
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, United StatesContact removed g•••@jhmi.edu · •••3644
  • Dana-Farber Cancer Institute · Boston, United StatesContact removed D•••@dfci.harvard.edu · •••2351
  • Memorial Sloan Kettering Cancer Center · New York, United StatesContact removed p•••@mskcc.org · •••4543
  • Duke University Medical Center · Durham, United StatesContact removed t•••@duke.edu · •••3095
  • University of Cincinnati Cancer Center · Cincinnati, United StatesContact removed b•••@ucmail.uc.edu · •••5725
  • SCRI Oncology Partners · Nashville, United StatesContact removed k•••@scri.com · •••7274
  • SCRI - Texas Oncology Dallas · Dallas, United StatesContact removed c•••@usoncology.com · •••1000
  • MD Anderson Cancer Center · Houston, United StatesContact removed g•••@mdanderson.org
  • Virginia Cancer Specialists · Fairfax, United StatesContact removed c•••@usoncology.com · •••8400
  • Virginia Mason Medical Center · Seattle, United StatesContact removed r•••@commonspirit.org · •••6273
Oct 2, 2026
Show all 3 updates
  1. Nov 16, 2026
    24 sites added — first sites in Denmark, Norway, Poland, Sweden and Switzerland
    Show 24 added (3 Belgium, 3 Germany, 3 Poland, 3 Spain, 2 Norway, 2 Switzerland, 1 Australia, 1 Austria, 1 Canada, 1 Denmark, 1 Hong Kong, 1 Italy, 1 Netherlands, 1 Sweden)
    • GenesisCare St Leonards · Saint Leonards, Australia
    • Krankenhaus Barmherzige Schwestern Linz · Linz, Austria
    • Imeldaziekenhuis · Bonheiden, Belgium
    • Universitair Ziekenhuis Gent · Ghent, Belgium
    • Universitair Ziekenhuis Brussel · Jette, Belgium
    • Centre Hospitalier de l'Université de Montréal (CHUM) · Québec, Canada
    • Aarhus Universitetshospital · Aarhus N, Denmark
    • Charité - Campus Virchow-Klinikum · Berlin, Germany
    • Universitätsklinikum Tübingen · Tübingen, Germany
    • Universitätsklinikum Würzburg · Würzburg, Germany
    • The University of Hong Kong, Department of Clinical Oncology · Hong Kong, Hong Kong
    • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
    • Onze Lieve Vrouwe Gasthuis · Amsterdam, Netherlands
    • Oslo University Hospital · Oslo, Norway
    • St. Olavs Hospital Hf, Universitetssykehuset i Trondheim · Trondheim, Norway
    • Pratia Onkologia Katowice · Katowice, Poland
    • Pratia MCM Krakow · Krakow, Poland
    • PRATIA S.A. MTZ Clinical Research Powered by Pratia · Warsaw, Poland
    • Hospital Clinic I Provincial de Barcelona · Barcelona, Spain
    • ICO l'Hospitalet - Hospital Duran i Reynals · Barcelona, Spain
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Sahlgrenska Univeristy Hospital Goteborg · Gothenburg, Sweden
    • Universitaetsspital Basel · Basel, Switzerland
    • Inselspital, Bern University Hospital · Bern, Switzerland
    Primary completion Jun 2028→Apr 2028
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedPrior treatment with systemic anticancer therapy in metastatic or locally advanced setting or prior RAS-targeted therapy in any treatment setting.
    Primary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedProgression free survival (PFS) as assessed by blinded independent central review (BICR)Time frame: Up to approximately 2 years
    • DescriptionOverall survival (OS): how it is measured was reworded
    Secondary outcomes 3 added, 2 description edited
    What changed in the outcomes
    • AddedPFS as assessed by BICRTime frame: Up to approximately 2 years
    • AddedOverall survival (OS)Time frame: Up to approximately 2 years
    • AddedPFS as assessed by the InvestigatorTime frame: Up to approximately 2 years
    • DescriptionDuration of response (DOR): how it is measured was reworded
    • DescriptionObjective response rate (ORR): how it is measured was reworded
    + 2 other changes: verification date and description
  2. Oct 2, 2026
    21 sites added — first sites in Belgium, Germany, Hong Kong and Italy. 18 sites changed recruiting status (18 now active, not recruiting)
    Show 18 sites
    • Mayo Clinic - Scottsdale · Phoenix, United StatesRecruiting→Active, not recruiting
    • Honor Health Research Institute · Scottsdale, United StatesRecruiting→Active, not recruiting
    • University of California Los Angeles Health - Hematology/Oncology · Los Angeles, United StatesRecruiting→Active, not recruiting
    • University of California San Francisco · San Francisco, United StatesRecruiting→Active, not recruiting
    • Mayo Clinic Cancer Center- Florida · Jacksonville, United StatesRecruiting→Active, not recruiting
    • H Lee Moffitt Cancer Center and Research Institute · Tampa, United StatesRecruiting→Active, not recruiting
    • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, United StatesRecruiting→Active, not recruiting
    • Dana-Farber Cancer Institute · Boston, United StatesRecruiting→Active, not recruiting
    • Mayo Clinic Cancer Center- Rochester · Rochester, United StatesRecruiting→Active, not recruiting
    • Memorial Sloan Kettering Cancer Center · New York, United StatesRecruiting→Active, not recruiting
    • Duke University Medical Center · Durham, United StatesRecruiting→Active, not recruiting
    • University of Cincinnati Cancer Center · Cincinnati, United StatesRecruiting→Active, not recruiting
    • SCRI Oncology Partners · Nashville, United StatesRecruiting→Active, not recruiting
    • SCRI - Texas Oncology Dallas · Dallas, United StatesRecruiting→Active, not recruiting
    • MD Anderson Cancer Center · Houston, United StatesRecruiting→Active, not recruiting
    • Huntsman Cancer Institute · Salt Lake City, United StatesRecruiting→Active, not recruiting
    • Virginia Cancer Specialists · Fairfax, United StatesRecruiting→Active, not recruiting
    • Virginia Mason Medical Center · Seattle, United StatesRecruiting→Active, not recruiting
    Show 21 added (5 Italy, 4 United Kingdom, 2 Belgium, 2 Spain, 1 Australia, 1 Canada, 1 Germany, 1 Hong Kong, 1 Netherlands, 1 Singapore, 1 South Korea, 1 Taiwan)
    • St. George Hospital · Kogarah, Australia
    • Institut Jules Bordet · Anderlecht, Belgium
    • UZ Leuven (Univ Ziekenhuis Leuven) · Leuven, Belgium
    • Sunnybrook Research Institute · Toronto, Canada
    • Klinikum der Universitaet Muenchen Campus Grosshadern · München, Germany
    • The Chinese University of Hong Kong · Hong Kong, Hong Kong
    • Fondazione IRCCS Istituto Nazionale dei Tumori · Milan, Italy
    • Istituto Oncologico Veneto IRCCS · Padova, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
    • Azienda Ospedaliera Card. G. Panico · Tricase, Italy
    • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) · Verona, Italy
    • St. Antonius Ziekenhuis · Utrecht, Netherlands
    • National Cancer Centre Singapore · Singapore, Singapore
    • Kyungpook National University Chilgok Hospital · Daegu, South Korea
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Clínico Universitario de Valencia · Valencia, Spain
    • National Cheng Kung University Hospital · Tainan, Taiwan
    • The Clatterbridge Cancer Centre · Liverpool, United Kingdom
    • Royal Free Hospital · London, United Kingdom
    • Guy's Hospital · London, United Kingdom
    • University College London Hospital · London, United Kingdom
    Site contacts Changed at 14 sites. See the sites
    Show 14 sites
    • Honor Health Research Institute · Scottsdale, United StatesContact removed c•••@honorhealth.com
    • University of California Los Angeles Health - Hematology/Oncology · Los Angeles, United StatesContact removed b•••@mednet.ucla.edu · •••0771
    • University of California San Francisco · San Francisco, United StatesContact removed •••7070
    • H Lee Moffitt Cancer Center and Research Institute · Tampa, United StatesContact removed c•••@moffitt.org · •••3691
    • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, United StatesContact removed g•••@jhmi.edu · •••3644
    • Dana-Farber Cancer Institute · Boston, United StatesContact removed D•••@dfci.harvard.edu · •••2351
    • Memorial Sloan Kettering Cancer Center · New York, United StatesContact removed p•••@mskcc.org · •••4543
    • Duke University Medical Center · Durham, United StatesContact removed t•••@duke.edu · •••3095
    • University of Cincinnati Cancer Center · Cincinnati, United StatesContact removed b•••@ucmail.uc.edu · •••5725
    • SCRI Oncology Partners · Nashville, United StatesContact removed k•••@scri.com · •••7274
    • SCRI - Texas Oncology Dallas · Dallas, United StatesContact removed c•••@usoncology.com · •••1000
    • MD Anderson Cancer Center · Houston, United StatesContact removed g•••@mdanderson.org
    • Virginia Cancer Specialists · Fairfax, United StatesContact removed c•••@usoncology.com · •••8400
    • Virginia Mason Medical Center · Seattle, United StatesContact removed r•••@commonspirit.org · •••6273
  3. Sep 30, 2026
    12 sites added — first sites in Netherlands and Spain
    Show 12 added (4 South Korea, 2 Australia, 2 Spain, 1 United States, 1 Netherlands, 1 Taiwan, 1 United Kingdom)
    • Henry Ford Health System · Detroit, United States
    • Royal Brisbane and Women's Hospital · Herston, Australia
    • Austin Health, Olivia Newton-John Cancer Research & Wellness Centre · Heidelberg, Australia
    • Erasmus Medisch Centrum · Rotterdam, Netherlands
    • Dong-A University Hospital · Busan, South Korea
    • Severance Hospital, Yonsei University Health System · Seoul, South Korea
    • Asan Medical Center - PPDS · Seoul, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Universitario La Paz - PPDS · Madrid, Spain
    • Taipei Veterans General Hospital · Taipei, Taiwan
    • Sarah Cannon Research Institute UK · London, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07491445
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Mar 9, 2026
Primary completion
Apr 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Revolution Medicines Study Director
Contact
medinfo@revmed.com
1-844-2-REVMED

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daraxonrasib · Gemcitabine · Albumin-Bound Paclitaxel

Start the discussion